Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Debio-0123 by Debiopharm International for Endometrial Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
Debio-0123 by Debiopharm International for Epithelial Ovarian Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
Debio-0123 by Debiopharm International for Fallopian Tube Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
Debio-0123 by Debiopharm International for Uterine Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Uterine Cancer. According to GlobalData, Phase...
Debio-0123 by Debiopharm International for Astrocytoma: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase II for Astrocytoma. According to GlobalData, Phase II...
Afabicin by Debiopharm International for Osteomyelitis: Likelihood of Approval
Afabicin is under clinical development by Debiopharm International and currently in Phase II for Osteomyelitis. According to GlobalData, Phase II...
Octreotide ER by Debiopharm International for Acromegaly: Likelihood of Approval
Octreotide ER is under clinical development by Debiopharm International and currently in Phase II for Acromegaly. According to GlobalData, Phase...
Naratuximab emtansine by Debiopharm International for Follicular Lymphoma: Likelihood of Approval
Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Follicular Lymphoma. According to GlobalData,...
Naratuximab emtansine by Debiopharm International for Mantle Cell Lymphoma: Likelihood of Approval
Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Mantle Cell Lymphoma. According to...
Naratuximab emtansine by Debiopharm International for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
Naratuximab emtansine by Debiopharm International for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Marginal Zone B-cell Lymphoma. According...
Naratuximab emtansine by Debiopharm International for Non-Hodgkin Lymphoma: Likelihood of Approval
Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...
Debio-0228 by Debiopharm International for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Debio-0228 is under clinical development by Debiopharm International and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...
Debio-0228 by Debiopharm International for Metastatic Colorectal Cancer: Likelihood of Approval
Debio-0228 is under clinical development by Debiopharm International and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Debio-0228 by Debiopharm International for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Debio-0228 is under clinical development by Debiopharm International and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Debio-0228 by Debiopharm International for Solid Tumor: Likelihood of Approval
Debio-0228 is under clinical development by Debiopharm International and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Debio-4326 by Debiopharm International for Central Precocious Puberty: Likelihood of Approval
Debio-4326 is under clinical development by Debiopharm International and currently in Phase III for Central Precocious Puberty. According to GlobalData,...
Debio-0123 by Debiopharm International for Solid Tumor: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Debio-4228 by Debiopharm International for Metastatic Prostate Cancer: Likelihood of Approval
Debio-4228 is under clinical development by Debiopharm International and currently in Phase II for Metastatic Prostate Cancer. According to GlobalData,...
Debio-0123 by Debiopharm International for Glioblastoma Multiforme (GBM): Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...